Lv4
528 积分 2025-11-28 加入
Recent update on the development of EZH2 inhibitors and degraders for cancer therapy
7天前
已完结
T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma
11天前
已完结
T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma
22天前
已完结
First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study
26天前
已完结
Are CHOP-Plus Really CHOP-Minus Propositions in the Treatment of PTCL? A Comprehensive Assessment of the Strategy
1个月前
已关闭
The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A
1个月前
已完结
T cell lymphomas: cancers of aberrant immune synapse signalling
1个月前
已完结
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study
2个月前
已完结
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
2个月前
已完结
Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond
5个月前
已完结
皖公网安备34019202002308
